Search
News & Events
Rapidly assembled advisory group to offer community take on COVID-19 researchThe speed with which research projects on the coronavirus have been put together has consumer advocates concerned that a vital voice will be missing – that of the community.
News & Events
Community advocate jumps on board with new COVID-19 advisory groupLike many of us, consumer and community advocate Catherine Hughes is worried about the impact of COVID-19. So she joined Australia’s first COVID-19 consumer reference group to be a voice for the community.
Research
Widening the lens for pandemic preparedness: children must be seen and heardThe Australian and New Zealand Paediatric Infectious Diseases (ANZPID) Group of the Australasian Society for Infectious Diseases (ASID) calls for urgent consideration of the needs and voices of children in response to the COVID-19 pandemic, and in planning for future pandemics.
News & Events
Tips for discussing coronavirus with your kidsThe rapidly developing coronavirus crisis is affecting our daily lives in unprecedented ways and brings with it uncertainty and fear.
Research
Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody responseSARS-CoV-2 nucleocapsid (N) protein antibodies can be used to identify the serological response to natural infection in those who have previously received a COVID-19 spike-based vaccine. Anti-N antibody responses can also be induced by inactivated whole SARS-CoV-2 virus vaccines, such as CoronaVac. We aimed to characterise antibody responses to the N protein following COVID-19 and following vaccination with CoronaVac.
Research
Global Disparities of Cancer and Its Projected Burden in 2050Cancer prevention and care efforts have been challenged by the COVID-19 pandemic and armed conflicts, resulting in a decline in the global Human Development Index (HDI), particularly in low- and middle-income countries. These challenges and subsequent shifts in health care priorities underscore the need to continuously monitor cancer outcome disparities and statistics globally to ensure delivery of equitable and optimal cancer prevention and care in uncertain times.
Research
Opportunities to strengthen respiratory virus surveillance systems in Australia: lessons learned from the COVID-19 responseDisease surveillance data was critical in supporting public health decisions throughout the coronavirus disease 2019 (COVID-19) pandemic. At the same time, the unprecedented circumstances of the pandemic revealed many shortcomings of surveillance systems for viral respiratory pathogens. Strengthening of surveillance systems was identified as a priority for the recently established Australian Centre for Disease Control, which represents a critical opportunity to review pre-pandemic and pandemic surveillance practices, and to decide on future priorities, during both pandemic and inter-pandemic periods.
Research
Specific IgA, but Not IgG, in Human Milk from COVID-19-Infected Mothers Neutralizes SARS-CoV-2This study highlights the importance of human milk in providing anti-severe acute respiratory syndrome coronavirus 2 immunity to newborns. The highest protective activity of human milk against COVID-19 was found in colostrum from infected mothers.
Research
Estimating the impact of test–trace–isolate–quarantine systems on SARS-CoV-2 transmission in AustraliaAustralian states and territories used test-trace-isolate-quarantine (TTIQ) systems extensively in their response to the COVID-19 pandemic in 2020-2021. We report on an analysis of Australian case data to estimate the impact of test-trace-isolate-quarantine systems on SARS-CoV-2 transmission.
Research
Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trialRepurposed drugs with host-directed antiviral and immunomodulatory properties have shown promise in the treatment of COVID-19, but few trials have studied combinations of these agents. The aim of this trial was to assess the effectiveness of affordable, widely available, repurposed drugs used in combination for treatment of COVID-19, which may be particularly relevant to low-resource countries.